| CAS NO: | 65914-17-2 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| Molecular Weight (MW) | 390.38 |
|---|---|
| Formula | C20H22O8 |
| CAS No. | 65914-17-2 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 78 mg/mL (199.8 mM) |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Solubility (In vivo) | Chemical Name: (2S,3R,4S,5S,6R)-2-(3-hydroxy-5-((E)-4-hydroxystyryl)phenoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol InChi Key: HSTZMXCBWJGKHG-CUYWLFDKSA-N InChi Code: InChI=1S/C20H22O8/c21-10-16-17(24)18(25)19(26)20(28-16)27-15-8-12(7-14(23)9-15)2-1-11-3-5-13(22)6-4-11/h1-9,16-26H,10H2/b2-1+/t16-,17-,18+,19-,20-/m1/s1 SMILES Code: O[C@H]([C@@H](O)[C@@H]1O)[C@@H](O[C@@H]1CO)OC2=CC(C=CC3=CC=C(O)C=C3)=CC(O)=C2 |
| Synonyms | Polydatin; Resveratrol 3-O-β-D-Glucopyranoside; Reservatrol 3-β-mono-D-Glucoside; Trihydroxystilbene-3-β-D-Glucopyranoside; Piceid; |
| In Vitro | In vitro activity: Polydatin, known as a PLA2 inhibitor, reduces Phospholipase A2 (PLA2) activity and sPLA2-IIA mRNA expression and mitigates LPS-induced lung injury by increasing increased Clara cell secretory protein (CCSP) expression. Cell Assay: The effect of polydatin on mMEC viability is evaluated with an MTT assay. mMECs are incubated in the presence or absence of various concentrations of polydatin (25, 50 and 100 μg/mL) and DEX (100 μg/mL) for 24 h. Next, 20 μL of MTT (5 mg/mL) is added to each well and incubated for 4 h. After the supernatants are removed and the formazan is dis!solved with 150 μL of DMSO in each well, the optical density (OD) value is measured at 570 nm on a microplate reader |
|---|---|
| In Vivo | Pretreatment with Polydatin (15, 45, and 100 mg/kg) dose-dependently reduces sepsis-induced mortality and lung injury in cecal ligation and puncture (CLP-)induced sepsis mice through inhibiting CLP-induced serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) production, lung cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase isoform (iNOS) protein expressions and NF-kappaB activation. LD50: Mice 1g/kg (i.p.). |
| Animal model | Rats and Mice |
| Formulation & Dosage | Rats: Rats are divided into six groups by random assignment and treated as follows: in normal group and polydatin control group: rats are administrated with CMC-Na and polydatin (200 μmol/kg) by gavage respectively, and given normal saline (NS) by tail intravenous (iv) injection with the same volume; in DOX group: rats are injected with DOX by cauda vein for 4 weeks (3 mg/kg per week), the cumulative dosage is 12 mg/kg similar to that in the research of Chang et al. Mice: Polydatin is dissolved in dimethyl sulfoxide (DMSO) and diluted in Dulbecco’s modified Eagle’s medium (DMEM). Sixty adult female postpartum and lactating BALB/c mice (6–8 weeks old, weighing 35–40 g) are obtained. Control group (CG): The mice are treated with 100 μL of PBS as a vehicle control. Polydatin groups: 24h after S aureus infection, the mouse model of S aureus mastitis is intraperitoneally administered polydatin at 15, 30 and 45 mg/kg |
| References | BMC Cell Biol. 2011 Jul 25;12:31; Mediators Inflamm. 2013;2013:354087. |
m.cnreagent.com